A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

Summary

This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.

Timeline

Start

2020-10-14

Primary completion

2022-11-15

Completion

2023-05-12

Publications

• Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D. Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. Front Pharmacol. 2025 Nov 20;16:1710434. doi: 10.3389/fphar.2025.1710434. eCollection 2025.

Drugs

Indications